A mini review on neurofibromatosis type 1 from the radiological point of view

Monika Bekiesinska-Figatowska1*

1Department of Diagnostic Imaging, Institute of Mother and Child, Kasprzaka 17a, 01-211 Warsaw, Poland

ABSTRACT

Neurofibromatosis type one (NF1) belongs to the most frequent rare diseases, requiring various methods of diagnostic imaging at different stages of diagnostics and follow-up. Magnetic resonance imaging (MRI) is a method of choice in diagnostics of brain: unidentified neurofibromatosis objects, optic pathway gliomas and other tumours which can spontaneously regress. NF1 patients suffer from vascular abnormalities with a predominance of aortic, renal, mesenteric, and carotid-vertebral stenoses or aneurysms. These are evaluated by ultrasound, computed tomography- or MRI-angiography and by digital subtraction angiography. In our material we described twofold higher occurrence of arterial variants in brain in NF1 than in the control group. Characteristic skeletal changes include tibial pseudarthrosis, scoliosis, sphenoid wing dysplasia, rib penciling, and gracile bones, usually diagnosed with plain radiographs. Outside CNS we deal with neurofibromas and plexiform neurofibromas in any location in the body. Their malignant transformation leads to development of malignant peripheral nerve sheath tumour, or malignant triton tumour. Rhabdomyosarcoma, juvenile myelomonocytic leukemia and phaeochromocytoma are also encountered in NF1 patients with increased frequency. Regular imaging follow-up studies should not be routinely performed in NF1 patients. MRI is recommended for follow-up of clinically suspected tumours, single whole-body MR is recommended at transition to adulthood. Positron emission tomography/computed tomography is useful for the detection of malignant transformation of tumours in NF1 patients.

Neurofibromatosis type one (NF1) belongs to the most frequent rare diseases, occurring with an incidence of approximately one in 3000 individuals at birth. It has cutaneous, ocular, neurologic, musculoskeletal, vascular and cardiac manifestations, including tumours. Various methods of diagnostic imaging are used at different stages of diagnostics and follow-up of many of these manifestations. Institute of Mother and Child in Warsaw, Poland, is a tertiary referral centre for NF1 patients and diagnostic imaging belongs to the routine work-up of these patients.

The diagnostic criteria for NF1 were defined in 1997 by the National Institute of Health (NIH) Criteria Consensus Conference and are as follows:

- six or more spots of „cafe au lait” type more than 5 mm in diameter,
- two or more neurofibromas or one plexiform neurofibroma,
- freckles or skin discolorations in the places inaccessible for light (armpits, groins, pubic region),
- two or more Lisch nodules on the iris,
- characteristic skeletal changes,
- a first-degree relative suffering from NF1.

At least two criteria must be met for clinical diagnosis.

Skin lesions such as café-au-lait spots or freckling on flexural areas, and Lisch nodules will not be a subject of these considerations as they do not require diagnostic imaging.

Radiological features of NF1 in central nervous system are well-known and widely described in the literature and have been in the field of interest of our centre as well as other manifestations of the disease. Unidentified neurofibromatosis objects (UNO), formerly called unidentified bright objects (UBO) detected on magnetic resonance imaging (MRI) are typical of NF1. Basal ganglia are the most frequent localisation of these lesions as well as cerebellum and brainstem. UNO show hyperintense signal on T2-weighted images (T2WI), and are usually isointense on T1-weighted images (T1WI), but lesions located in the globi pallidi often display hyperintense signal also on T1WI. UNO can also be found in the corpus callosum, especially in the callosal splenium, but in our experience this finding is less frequent.

There is some degree of difficulty when assessing the thalami and medial parts of the temporal lobes (hippocampi, parahippocampal structures, amygdala, sometimes with extension into the insula) which are thickened and slightly diffusely hyperintense on T2WI in NF1 patients (figure 1). This observation has already been mentioned in the literature. Gill et al. report possible different pathological basis of temporal lesions which do not resolve with age as opposed to lesions in the basal ganglia, thalami, cerebellum and brainstem that do resolve.

**Figure 1.** MRI, FSE/T2WI, axial plane. Slightly thickened and discretely hyperintense medial parts of temporal lobes in a 9-year-old girl with NF1.

Pilocytic astrocytoma, forming optic pathway glioma (OPG), constitutes a major management issue. Until 8 years of age, clinical assessment for this pathology is recommended every 6 to 12 months, but routine MRI assessment is not advised in asymptomatic patients with NF1 and no clinical signs of visual pathway disturbances. Treatment for symptomatic OPG (with strabismus, exophthalmos, amblyopia, endocrinological disturbances) is not well standardized. Various lines of chemotherapy are used with minimal effect on the solid components of the tumours initially but no effect on cystic ones and with subsequent growth of the tumour regardless of treatment. Clinical findings do not differ between treated patients and those who are subjected to the “watch and wait” policy.

There is another difficulty in the assessment of mass lesions in the brainstem of NF1 patients. Diffuse, often asymmetrical pontine and/or medullary enlargement with frequently very discrete hyperintensity on T2WI may also spontaneously regress over time thus indicating UNO rather than brain stem glioma. MR spectroscopy (MRS) is helpful in these situations with a high choline to creatine ratio over 2 (Cho/Cr > 2) typical of a tumour.

NF1 patients suffer from vascular abnormalities with a predominance of aortic, renal, mesenteric, and carotid-
vertebral stenoses or aneurysms in the younger patients, and degenerative atherosclerotic aortic aneurysms in the older ones. Renal artery stenosis caused by NF1 vasculopathy is a well-known cause of hypertension. Ultrasonography (US), CT- and/or MR-angiography and in some cases digital subtraction angiography (DSA) are employed in diagnostic process of vascular manifestations of NF1. Cerebral arteriopathy which is reported to be more prevalent in NF1 patients than in general population has not been found in our experience (except one case), at least that with clinical significance. We have described twofold higher occurrence of arterial variants in NF1 patients than in the control group, the most frequent variant being fetal configuration of the circle of Willis (defined as P1 part of the posterior cerebral artery smaller than posterior communicating artery via posterior communicating artery). Multiple variants were more frequent in NF1 patients than in healthy controls although this difference did not reach statistical significance. The only NF1 patient with significant vascular condition in our material had moyamoya disease. However, followed-up for 6 years now, he is still free from stroke and its neurological consequences.

Characteristic skeletal changes of NF1 include congenital pseudarthrosis of the tibia, scoliosis, sphenoid wing dysplasia, rib penciling, and gracile bones. Usually plain radiographs are sufficient to diagnose these manifestations of the disease and computed tomography (CT) is used for special indications. NF1 predisposes patients to benign and malignant tumour development, however, bone malignancies are extremely rare in this population. Outside CNS we deal with neurofibromas and plexiform neurofibromas in any location in the body of NF1 patients. The routine screening method is US. We use MRI when we are looking for compression of vital structures, e.g. of the spinal cord by the tumours extending from the intervertebral foramina or of the trachea, and for infiltration of other organs when considering resectability of the tumour (figure 3) and - first of all - for the signs of malignancy in rapidly growing tumours (figure 4). Malignant transformation leads to the development of such tumours as malignant peripheral nerve sheath tumour (MPNST), or malignant triton tumour. Other soft tissue sarcomas, e.g. rhabdomyosarcoma (RMS), as well as other malignancies such as juvenile myelomonocytic leukemia or pheochromocytoma are also encountered in NF1 patients with increased frequency comparing to general population. However, for example the Endocrine Society, European Society of Endocrinology, and American Association for Clinical Chemistry do not recommend screening asymptomatic NF1 patients for pheochromocytoma and paraganglioma.

It is no more questionable whether regular imaging follow-up studies, often required by the clinicians, should be routinely performed in NF1 patients. It has been stated in the literature at least 15 years ago by French...
experts. It has also been stated earlier, in 1992, by the participants of a joint World Health Organization and National Neurofibromatosis Foundation meeting that “although some clinicians have advocated routine screening scans for all patients with NF1, the utility of such screening has not been conclusively demonstrated”23. Also the experience of our centre does not show real advantage of this approach. After years of gaining experience, our way of thinking has changed and we do not share the point of view of oncologists/oncological surgeons published years ago that “watchful waiting with regular MR monitoring ... if there are no oncological reasons for anxiety” should be standard management of NF1 patients24. It is more reasonable to perform follow-up MRI in cases of new/progressing clinical signs and symptoms. Repeated sedation (in paediatric patients, as in our case) and gadolinium-based contrast media administration should be weighed against real clinical benefit from this kind of management. The finding of gadolinium deposition in the brain despite normal renal function, that has been a concern so far in terms of nephrogenic systemic fibrosis25, has pointed at its possible long-term toxicity. We know that more stable macrocyclic contrast agents should be the primary choice but avoiding unnecessary use is the key point26. In the literature, annual clinical examination is recommended except in cases with complications. Taking into account the rarity of complications that are usually symptomatic and easily detected during the clinical follow-up, screening investigations are not recommended27. The only controversial exception was MRI for early detection of optic pathway gliomas in children22 but it is not advised any more now8. At present MRI is generally recommended for follow-up of clinically suspected tumours, both intra- and extracranial27 and it is recommended to consider a single whole-body MR examination at transition to adulthood which might assist in determining approaches to long-term follow-up in the future life of a patient8. Positron emission tomography/computed tomography (PET/CT) is useful for the detection of malignant transformation of tumours in NF1 patients28.

Despite our wide knowledge concerning NF1 there are still numerous issues to be addressed. Learning disabilities, attention deficits, and social and behavioural problems including autism spectrum disorder, decrease the quality of life of NF1 patients. Advanced MRI techniques, like Diffusion Tensor Imaging (DTI) or functional MRI (fMRI), are more and more widely used to explore these domains29,30. For example, the relationship between increased brain volume, including the volume of the corpus callosum, and decreased IQ in NF1 patients still remains to be explained (figure 5). This is the purpose of our ongoing research with use of MR-volumetry.

Conflict of interest
The author declares no conflict of interest.

The author received no funding.

References


